Back to School: How biopharma can reboot drug development. Access exclusive analysis here

CHMP backs Besremi for polycythemia vera, two Shionogi drugs

EMA's CHMP recommended a basket of approvals and label extensions on Friday, including Orphan Drug Besremi ropeginterferon alfa-2b to treat polycythemia vera and a pair of treatments from Shionogi & Co. Ltd. (Tokyo:4507).

The agency backed Besremi from AOP Orphan Pharmaceuticals AG (Vienna, Austria) to treat polycythemia vera without symptomatic splenomegaly. AOP has rights

Read the full 531 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE